GlobeNewswire by notified

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

Share

Negma Group has converted 56convertible bonds in Oxurion resulting in a EUR 140,000capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.

Leuven, BELGIUM,Boston, MA, USNovember 18, 2022– 10.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 14,705,882 new ordinary shares on November 17, 2022, for a total amount of EUR 140,000, as the result of the conversion of 56 class B convertible bonds, pursuant to the Capital Commitment entered into with Negma Group.

Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 123,781,647 outstanding ordinary shares carrying voting rights (compared to 109,075,765 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

  • Share capital (EUR)
73,121,161.32
  • Total number of securities with voting rights (all ordinary shares)
123,781,647
  • Total number of ordinary shares (= denominator)
123,781,647
  • Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued:
  • 719,500 subscription rights (“SRs”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 719,500 securities carrying voting rights (all ordinary shares);
  • 60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);
  • 1,007,250 SRs issued on April 14, 2021, entitling their holders to subscribe to a total number of 1,007,250 securities carrying voting rights (all ordinary shares);
  • 550,000 SRs issued on September 22, 2021, entitling their holders to subscribe to a total number of 550,000 securities carrying voting rights (all ordinary shares);
  • 725,749 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 725,749 securities carrying voting rights (all ordinary shares);
  • 754 convertible bonds issued on September 5, 2022, and 21 October 2022, entitling their holder (Negma Group) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions set forth in the issuance and subscription agreement entered into between the Company and Negma Group on August 26, 2021, and the addendum thereto dated September 2, 2022; and
  • 100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P., on November 21, 2021.

END

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com



Michaël Dillen
Chief Business Officer
Tel: +32 16 75 13 10
michael.dillen@oxurion.com
US
Conway Communications
Beth Kurth
bkurth@conwaycommsir.com





ICR Westwicke
Christopher Brinzey
Tel: +1 617 835 9304
chris.brinzey@westwicke.com



1Press release Oxurion, 06/04/2021 and Press release Oxurion, 02/09/2022

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Robex: Strong Q2 Operational Results and Closing of the Transaction With Sycamore29.11.2022 01:47:16 CET | Press release

QUÉBEC CITY, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Robex Resources Inc. ("Robex", "the Group" or "the Company") (TSXV: RBX) is pleased to publish their financial results for the second quarter ended June 30, 2022. All amounts are in Canadian dollars (CAD). Quarterly Corporate Summary Operations: The number of ounces produced was 11,124 ounces, down by 1.7% compared to the same quarter in the previous year, specifically due to a much heavier rainy season in September that the start-up of the trommel as well as a higher feeding grade (0.82 g/t compared to 0.79 g/t for the same period in 2021) have not allowed to compensate. As a matter of fact, the unprecedented rainfall caused hopper procurement issues, loader cycle timing and availability issues, as well as clogging of the primary grizzly. At the beginning of October, the situation was back to normal. Exploration: During the third quarter of 2022, Robex continued significant exploration work completed by remote sensing on all its licences

Brookfield to Present at the Goldman Sachs 2022 US Financial Services Conference28.11.2022 22:01:00 CET | Press release

BROOKFIELD, NEWS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE: BAM, TSX: BAM.A) today announced that Bruce Flatt, Chief Executive Officer, is scheduled to present at the Goldman Sachs US Financial Services Conference on Wednesday, December 7, 2022, at 1:40pm ET. A live webcast will be available on the Brookfield website at https://bam.brookfield.com/news-events/events. For those unable to join the live webcast, a recording will be available on Brookfield’s website shortly after the event. About Brookfield Brookfield (NYSE: BAM, TSX: BAM.A) is a leading global alternative asset manager with over $750 billion of assets under management across real estate, infrastructure, renewable power and transition, private equity and credit. Brookfield owns and operates long-life assets and businesses, many of which form the backbone of the global economy. Utilizing its global reach, access to large-scale capital and operational expertise, Brookfield offers a range of alt

Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US28.11.2022 22:00:00 CET | Press release

New patent granted in the United States by the USPTO covers the use of lanifibranor for the potential treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage This patent strengthens and expands the intellectual property protection of lanifibranor in the United States particularly for use for patients with cirrhotic NASH Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced that the United States Patent and Trademark Office (“USPTO”) granted a patent (U.S. Patent No. 11,504,380) that protects the use of lanifibranor for the treatment of cirrhotic patients at risk of progressing from compensated stage to decompensa

EYES ON IRAN ART ACTIVATION FACES THE U.N. IN NEW YORK28.11.2022 21:04:15 CET | Press release

AN EVENT MARKED THE OPENING FEATURING HILLARY RODHAM CLINTON, GISSOU NIA,SHEIDA SOLEIMANI, SHIRIN NESHAT with SPECIAL PERFORMANCE BY JON BATISTE NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Iranian artists Sheida Soleimani, Aphrodite Désirée Navab, Z, Icy and Sot, Shirin Neshat, Mahvash Mostala, Sepideh Mehraban, and Shirin Towfiq, alongside artists Hank Willis Thomas and JR, activate New York’s FDR Four Freedoms State Park with a provocative multi-day and multi-media art installation facing the United Nations entitled Eyes on Iran, November 28, 2022 - January 1, 2023. Timed for the U.N. initiative, 16 Days of Activism Against Gender-Based Violence, the installations are focused on the power of collective sight, with eyes facing the U.N., signifying the world’s eyes on Iran. 'Eyes in the Sky' flying billboards featuring artworks by Thomas and Mostala will fly on December 3 in New York City and on November 28 and 30 in Miami. An interactive installation by artist JR will take place on